세계 하대정맥 필터(IVCF) 시장 규모는 2024-2030년의 예측 기간 동안 연평균 5.67% 성장할 것으로 예상됩니다. 하대정맥 필터(IVCF)에 대한 수요는 주로 폐색전증 및 정맥 혈전색전증 발병률 증가에 의해 촉진되고 있습니다. 또한, 제품 개발의 지속적인 개선과 기술 발전, 주요 국가들의 기기 승인으로 인해 하대정맥 시장의 전반적인 성장에 기여할 것으로 예상됩니다. 이는 2024-2030년의 예측 기간 동안 하대정맥 시장의 긍정적인 성장에 기여하는 주요 촉진요인입니다.
하대정맥 필터(IVCF) 시장 역학
하대정맥 필터(IVCF)는 폐색전증 및 정맥혈전색전증 예방에 중요한 역할을 하고 있으며, 호주 보건부(Australian Government Department of Health and Aged Care)의 조사에 따르면 정맥혈전색전증(VTE)은 건강에 심각한 위협이 되고 있습니다. 건강에 심각한 위협이 되고 있습니다. 매년 17,000명 이상의 호주인이 폐색전증을 앓고 있으며, 노년층에서 발병률이 증가합니다.
또한, 미국 국립보건원(NIH)(2020)의 연구 '폐색전증 유병률(Pulmonary embolism prevalence among emergency department cohorts: A systematic review and meta-analysis by country of study'에 따르면, 폐색전증 유병률은 유럽에서 23%, 북미에서 8%로 나타났습니다. review and meta-analysis by country of study'에 따르면, 폐색전증 유병률은 유럽에서 23%, 북미에서 8%로 나타났습니다. 결과적으로 이러한 통계와 데이터는 향후 하대정맥 필터(IVCF)의 사용을 증가시켜 향후 시장을 촉진할 것으로 예상됩니다.
또한, 주요 업계 기업들의 기기 승인 증가도 하대정맥 필터(IVCF)의 전체 미래 시장을 견인하는 데 큰 역할을 하고 있으며, 2022년 12월에는 회수 가능한 하대정맥 필터(IVCF)인 ZYLOX Octoplus TM이 중국의 중국 국가약품감독관리국(National Medical Products Administration, NMPA)의 승인을 받았습니다. 이 필터는 주로 말초혈관의 심부정맥혈전증(DVT)으로 인한 폐색전증(PE)을 예방하도록 설계되었습니다. 이처럼 저명한 제조업체들이 IVCF 제품에 대한 규제 승인을 받음에 따라 의료 서비스 제공업체들은 이 첨단 솔루션을 치료 프로토콜에 통합하는 데 열중하고 있습니다. 그들의 관심은 환자의 결과를 개선하고 정맥혈전색전증과 관련된 위험을 최소화하는 데 있습니다.
또한 2024년 1월, Cook Medical은 Celect Platinum Vena Cava Filter와 Gunther Tulip Vena Cava Filter에 대한 FDA 승인을 획득했습니다. 유연성이 향상되어 삽입이 용이한 것이 특징입니다. 또한, 90% 이상의 회수율을 자랑하며, 성공적인 회수에 대한 추가적인 보증을 제공합니다. 이처럼 최근 몇 년간 하대정맥 필터(IVCF)의 승인과 수요 증가는 하대정맥 필터(IVCF)의 향후 시장 성장을 반영하고 있습니다.
그러나 하대정맥 필터(IVCF)가 원래 위치에서 이동, 필터 파손, 필터 구멍, 필터 내 혈전 형성 등의 문제 발생 위험 및 회수 관련 문제는 하대정맥 필터(IVCF)에 대한 시장 수요를 억제할 수 있습니다.
하대정맥 필터(IVCF) 시장 부문별 분석
하대정맥 필터(IVCF) 시장의 제품 부문에서 회수 가능한 하대정맥 필터(IVCF) 카테고리는 2023년 하대정맥 필터(IVCF) 시장에서 큰 수익 점유율을 차지할 것으로 추정됩니다. 이는 회수 가능한 하대정맥 필터(IVCF)가 제공하는 다양한 장점과 용도에 기인하는 것으로 추정됩니다.
이 보고서는 세계 하대정맥 필터(IVCF) 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 전해드립니다.
Inferior Vena Cava Filters Market By Product Type (Retrievable Inferior Vena Cava Filters, Permanent Inferior Vena Cava Filters), Material (Non-Ferromagnetic Material, Ferromagnetic Materials), Application (Venous Thromboembolism, Pulmonary Embolism), End User (Hospitals, Ambulatory Surgical Centers, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady cagr forecast till 2030 owing to the growing incidence of pulmonary embolism, venous thromboembolism (vte) and technological advancement with increasing approvals of device from leading countries across the globe.
The global Inferior Vena Cava Filters Market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030. The demand for Inferior Vena Cava Filters is primarily being boosted by the growing incidence of pulmonary embolism and venous thromboembolism. Furthermore, the inferior vena cava filter market is anticipated to grow on account of a large number of ongoing improvements in product development, technological advancement, and approvals of device from leading countries contributing to the overall growth of the inferior vena cava market. These are some of the major drivers that are responsible in contributing to the positive growth of the inferior vena cava market during the forecast period from 2024-2030.
Inferior Vena Cava Filters Market Dynamics:
The inferior vena cava filters (IVCF) plays an important role in the prevention of pulmonary embolism and venous thromboembolism. According to the study of Australian Government Department of Health and Aged Care (2021), venous thromboembolism (VTE) poses a significant threat to health. Annually, over 17,000 Australians will have pulmonary embolism every year, and the incidence increases in the aging population.
Furthermore, the study conducted under National Library of Medicines (NIH) 2020, "Pulmonary embolism prevalence among emergency department cohorts: A systematic review and meta-analysis by country of study", stated that the prevalence of pulmonary embolism in Europe was 23% and in North America was 8%. As a result these statistics and data are expected to increase the future use of inferior vena cava filters thus fueling the future market of the Inferior Vena Cava Filters.
Additionally, the increasing approvals of devices from leading industries companies are also playing the major role in boosting the overall future market of inferior vena cava filters. In December 2022, Retrievable Inferior Vena Cava Filter-ZYLOX OctoplusTM received approval from China's National Medical Products Administration (NMPA). This filter, is designed to prevent pulmonary embolism (PE) mainly caused by deep vein thrombosis (DVT) in the peripheral vasculature. Thus, with prominent manufacturers obtaining regulatory clearance for IVCF products, healthcare providers are keen to incorporate these advanced solutions into their treatment protocols. Their focus lies on improving patient outcomes and minimizing the risks associated with venous thromboembolism.
Additionally, In January, 2024 Cook Medical received FDA clearance for its Celect Platinum Vena Cava filter and Gunther Tulip Vena Cava Filter. The Celect Vena Cava Filter stands out for its enhanced flexibility and ease of insertion compared to earlier filter models. Additionally, boasting a retrieval rate exceeding 90%, it offers added assurance in terms of retrieval success. Thus the recent approvals and growing demand of inferior vena cava filters are reflecting the future market growth of inferior vena cava filters.
However, the risk of complication such as movement of IVCF from its original site, filter fracture, filter perforation or the blood clot formation within the filter and issues related with retrieval may hinder the market demand of Inferior Vena Cava Filters.
Inferior Vena Cava Filters Market Segment Analysis:
Inferior Vena Cava Filters Market By Product Type (Retrievable Inferior Vena Cava Filters, Permanent Inferior Vena Cava Filters), Material (Non-Ferromagnetic Material, Ferromagnetic Materials), Application (Treatment Of Venous Thromboembolism, Prevention Of Pulmonary Embolism), End-User (Hospitals, Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest Of The World)
In the product segment of the Inferior Vena Cava Filters market, the Retrievable Inferior Vena Cava Filters category is estimated to mass a significant revenue share in the Inferior Vena Cava Filters Market in 2023. This can be attributed to the various advantages and applications provided by the Retrievable Inferior Vena Cava Filters. Inferior vena cava (IVC) filters are medical devices which helps in preventing blood clots from traveling to the lungs, which can cause a condition known as pulmonary embolism. These filters are typically implanted in the inferior vena cava, the large vein that carries deoxygenated blood from the lower body to the heart. Pulmonary embolism (PE) is a serious medical condition which is characterized by the sudden blockage of one or more arteries in the lungs by blood clots. These clots usually originate in the deep veins of the legs, a condition known as deep vein thrombosis (DVT), and then travel through the bloodstream to the lungs.
These filters can be removed once the risk of pulmonary embolism has passed. They are often used for temporary protection against pulmonary embolism making patients suitable who only require short-term prophylaxis, such as those undergoing high-risk surgeries or trauma. Besides this the Retrievable filters offer flexibility such as if the risk of pulmonary embolism decreases or resolves, the filter can be safely removed. Additionally, removing a retrievable filter once it is no longer needed reduces the risk of long-term complications associated with permanent filter placement. The retrieval procedure for retrievable filters is typically less invasive than the initial placement procedure. It often involves a simple catheter-based technique, performed under fluoroscopic guidance, and can be done on an outpatient basis. Hence all the factors and advancement in technology are promoting the overall market size of Inferior Vena Cava Filter during the forecast period as the patients who require temporary protection against pulmonary embolism, the ability to have the filter removed once the risk has passed can improve overall comfort and quality of life.
North America Is Expected To Dominate The Overall Inferior Vena Cava Market:
North America is expected to account for the highest proportion of the Inferior Vena Cava Filters Market in 2023, out of all regions. This is due to the presence of a large patient pool suffering from incidence of pulmonary embolism and venous thromboembolism. DVT is the most common cause of pulmonary embolism. According to the latest data provided by the American Lung Association (2023), in the United States the annual incidence of pulmonary embolism is around 900,000 every year.
Additionally, as per the latest data provided by the American Lung Association (2023), approximately 33% of individuals who have had a deep vein thrombosis or pulmonary embolism will face a recurrence of pulmonary embolism within a decade. Hence, these statistics and data are expected to increase the future use of inferior vena cava filters thus fuelling the future market of the Inferior Vena Cava Filters in North America.
Additionally, leading companies in the inferior vena cava filter market are prioritizing partnership agreements to expand their distribution networks and improve customer satisfaction. By forging strategic alliances, these companies aim to broaden their market reach and deliver enhanced value to their customer base. For instance, in June 2022, Cordis-X a US- based manufacturer announced the investment in Adient Medical, a US based manufacturer of next generation IVC filter that provide protection against pulmonary embolism. Through this partnership, Cordis aims to expand its product further with solutions that meet unmet needs in cardiovascular health.
Furthermore, in North America individuals undergoing major surgery (e.g., orthopaedic surgery), trauma patients, and those with contraindications to anticoagulant therapy require IVC filters as these filters play a crucial role in the prevention and management of VTE in North America.
Inferior Vena Cava Filters Market Key Players:
Some of the key market players operating in the Inferior Vena Cava Filters include Cook, Radcliffe Medical Media., Teleflex Incorporated, Merit Medical Systems, Inc., Cardinal Health, Inc., Argon Medical Devices, Inc., BD, Medtronic, Abbott Laboratories, Terumo Corporation, Johnson & Johnson Services, Inc., Boston Scientific Corporation, Cordis., C.R. Bard, Inc., Mermaid Medical, LifeTech Scientific Corporation, Argon Medical Devices., Masimo., B. Braun Interventional Systems Inc., Braile Biomdica.
Recent Developmental Activities In The Inferior Vena Cava Filters Market:
Key Takeaways From The Inferior Vena Cava Filters Market Report Study
Target Audience Who Can Be Benefited From This Inferior Vena Cava Filters Market Report Study
Frequently Asked Questions For The Inferior Vena Cava Filters Market:
Inferior vena cava (IVC) filters are medical devices which helps in preventing blood clots from traveling to the lungs, which can cause a condition known as pulmonary embolism. These filters are typically implanted in the inferior vena cava, the large vein that carries deoxygenated blood from the lower body to the heart.
The global Inferior Vena Cava Filters Market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030.
The demand for Inferior Vena Cava Filters is primarily being boosted by the growing incidence of pulmonary embolism and venous thromboembolism. Furthermore, the inferior vena cava filter market is anticipated to grow on account of a large number of ongoing improvements in product development, technological advancement, and approvals of device from leading countries contributing to the overall growth of the inferior vena cava market. These are some of the major drivers that are responsible in contributing to the positive growth of the inferior vena cava market during the forecast period from 2024-2030.
Some of the key market players operating in the Inferior Vena Cava Filters include Cook, Radcliffe Medical Media., Teleflex Incorporated, Merit Medical Systems, Inc., Cardinal Health, Inc., Argon Medical Devices, Inc., BD, Medtronic, Abbott Laboratories, Terumo Corporation, Johnson & Johnson Services, Inc., Boston Scientific Corporation, Cordis., C.R. Bard, Inc., Mermaid Medical, LifeTech Scientific Corporation, Argon Medical Devices., Masimo., B. Braun Interventional Systems Inc., Braile Biomdica.
North America is expected to account for the highest proportion of the Inferior Vena Cava Filters Market in 2023, out of all regions. This is due to the presence of a large patient pool suffering from incidence of pulmonary embolism and venous thromboembolism.